Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease

Comparison of Midregional Pro-Atrial and B-Type Natriuretic Peptides in Chronic Heart Failure

“…This is in accordance with other investigations showing that the inverse relation of LVEF with BNP was stronger than with ANP or NT-proANP (12,13). In contrast, another study indicated a better detection of reduced LVEF by MR-proANP than by NT-proBNP (27). We believe that differences in the analytical method used are the most probable reasons for the comparatively high diagnostic power of MR-proANP.…”

Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy

“…Moreover, MR-proANP has been shown to be an independent predictor of mortality in patients with chronic heart failure adding prognostic information to NT-proBNP [41]. These studies [40,41] applied the HCM Hypertrophic cardiomyopahty, MR-proANP midregional pro-atrial natriuretic peptide, PPV positive predictive value, NPV negative predicitive value same assay format as used in the present study, aiming at the detection of MR-proANP instead of ANP or other precursors which are less stable and sensitive [25]. In our study, MR-proANP serum levels did not correlate with left atrial volume, a surrogate marker of chronic diastolic dysfunction, LV-EDD and LV-EF.…”

“…Pathophysiologically, ANP suppresses the renin and aldosterone release, causes an increase in sodium and water excretion and induces dilatation of the venous and arterial system [39]. In patients with coronary artery disease, MR-proANP has shown to be an independent indicator of impaired LV function [40]. Moreover, MR-proANP has been shown to be an independent predictor of mortality in patients with chronic heart failure adding prognostic information to NT-proBNP [41].…”

Plasma N-Terminal B-Type Natriuretic Peptide as an Indicator of Long-Term Survival After Acute Myocardial Infarction: Comparison With Plasma Midregional Pro-Atrial Natriuretic Peptide

“…Our data are consistent with previous analyses (e.g., with ejection fraction and a single marker NTproBNP) (6), which have retained imaging parameters in predicting similar outcomes. Midregional proatrial natriuretic peptide has been investigated in patients after an AMI where it has also been shown to be comparable to NT-proBNP for the detection of impaired left ventricular function (18). This study, unlike ours, is a small investigation in post-AMI patients at a remote time point after the acute event (mean follow-up 687 days).…”